Polymeric Dual Drugs for Targeted Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The development of potent, targeting drug conjugates with a high therapeutic index is hindered by the complexity of antibody-drug conjugate constructs, particularly the chemical linker between the antibody and drug, leading to slow progress in new therapeutic options.
Innovation Solution
The development of specific dimeric and polymeric biologically active compounds with spacing groups and chromophore moieties, including fluorescent dyes, as covalent linkers between biologically active moieties and targeting moieties, allowing for controlled attachment of therapeutic agents and enhanced delivery to target cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibody-drug conjugate constructs are used to deliver drugs to target cells, then targeted therapy effectiveness is improved, but the complexity of the chemical linker between antibody and drug increases, leading to slow development progress
Solution Approach 1:
The patent divides the drug delivery system into distinct modular components: a polymer backbone with repeating units, each containing a biologically active moiety, a spacing group, and a linker arm. This segmentation allows independent optimization of each component and simplifies the overall construct complexity while maintaining targeted therapy effectiveness.
Solution Approach 2:
The polymer backbone serves multiple functions simultaneously: it provides structural support, controls spacing between therapeutic agents, enables controlled drug release, and facilitates attachment to targeting moieties. This multi-functionality reduces the need for separate specialized components, thereby reducing overall system complexity.
2Manufacturing precision
If polymeric compounds with spacing groups are used to control attachment of therapeutic agents, then manufacturing precision is improved, but the device complexity increases
Solution Approach 1:
The patent utilizes adjustable parameters within the polymer structure, such as the length and composition of spacing groups (e.g., polyethylene glycol chains with varying degrees of polymerization), to precisely control the distance and orientation between therapeutic agents and targeting moieties. This allows fine-tuning of attachment precision through parameter optimization rather than structural redesign.
Solution Approach 2:
The polymer backbone incorporates composite structural elements combining hydrophilic spacing groups (e.g., PEG) with hydrophobic or functional segments. This composite approach enables simultaneous achievement of precise spacing control, solubility, and functional versatility without requiring entirely new complex polymer architectures.
3Difficulty of detecting and measuring
If chromophore moieties are incorporated into the polymer structure, then detection capability is improved, but the complexity of the compound structure increases
Solution Approach 1:
The patent merges the detection function (chromophore/fluorophore) with the structural backbone by incorporating these moieties directly into the polymer structure at defined positions. This integration allows simultaneous structural support and detection functionality without requiring separate detection components, thereby reducing overall system complexity.
Solution Approach 2:
The chromophore moieties incorporated in the polymer serve dual purposes: they provide detection capability through their optical properties and simultaneously contribute to the structural framework and spacing control. This multi-functionality reduces the need for additional separate detection components.
Data Source
AI summary
Compounds useful as biologically active compounds with or without fluorescent or colored dyes are disclosed. In some embodiments, the compounds have the following structure (I): (I) or a stereoisomer, tautomer or salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, M1, M2, M3, l, m, n, p, and q are as defined herein. Additional compound, methods of preparation, pharmaceutical compositions, and methods of treatment related to compounds of Structure (I) are also provided.